MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 15% planned / 85% discretionary
Largest single sale: $32.4M.
Where they traded
Last open-market purchase: October 8, 2025 , by Bodenstedt Matthias .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 1,100 | $20.00 | $22.0K | 2,711,198 −0% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 2,448 | $20.00 | $49.0K | 2,712,298 −0.1% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 50,000 | $20.02 | $1.0M | 2,714,746 −1.8% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 43,700 | $20.09 | $877.9K | 2,764,746 −1.6% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 16,105 | $20.01 | $322.3K | 2,808,446 −0.6% of holding | |
| Santos da Silva Jorge | Chief Executive Officer | Sell 10b5-1 | 68,289 | $20.02 | $1.4M | 2,774,893 −2.4% of holding | |
| Santos da Silva Jorge | Chief Executive Officer | Sell 10b5-1 | 33,936 | $20.01 | $679.1K | 2,843,182 −1.2% of holding | |
| Santos da Silva Jorge | Chief Executive Officer | Sell 10b5-1 | 47,775 | $20.03 | $956.9K | 2,877,118 −1.6% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 39,120 | $22.04 | $862.2K | 1,115,435 −3.4% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 2,794 | $19.60 | $54.8K | 1,154,555 −0.2% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 50,000 | $19.43 | $971.5K | 2,824,551 −1.7% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 15,082 | $19.68 | $296.8K | 1,157,349 −1.3% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 50,000 | $18.70 | $935.0K | 2,874,551 −1.7% of holding | |
| Reich Kristian | Chief Scientific Officer | Sell 10b5-1 | 50,000 | $18.89 | $944.5K | 2,924,551 −1.7% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 13,653 | $20.02 | $273.3K | 1,172,431 −1.2% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 2,426 | $19.56 | $47.5K | 1,186,084 −0.2% of holding | |
| Santos da Silva Jorge | Chief Executive Officer | Sell | 51,873 | $18.23 | $945.6K | 2,924,893 −1.7% of holding | |
| Santos da Silva Jorge | Chief Executive Officer | Sell | 98,127 | $18.41 | $1.8M | 2,976,766 −3.2% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 1,925 | $19.51 | $37.6K | 1,188,510 −0.2% of holding | |
| Bodenstedt Matthias | Chief Financial Officer | Sell 10b5-1 | 85,870 | $18.94 | $1.6M | 1,190,435 −6.7% of holding | |
| 3 fills | Sell | 3,750,000 | $16.79 | $63.0M | 8,302,735 −31.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.